Reflex esophagitis patients
Conditions
Interventions
Vonoprazan 20mg p.o. once daily, 4weeks,and Vonoprazan 10mg p.o. once daily, 4weeks
Esomeprazole 20mg p.o. once daily, 8weeks
Sponsors
Hirano Gastroenterology Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1:Patients who have freely provided written informed consent for the participation of this study after the oral or written sufficient explanation. 2:Patients who were confirmed reflux esophagitis with grade A-D of LA classification at the entry or in the past. 3:Patients who answered score of 4 (moderate problem) or severer in questions about heartburn, Q2 and/or regurgitation, Q3.
Exclusion criteria
Exclusion criteria: 1:Patients with warning signs such as vomiting, gastrointestinal bleeding and sudden weight loss. 2:Patients with confirmed or suspected malignant diseases. 3:Patients with a history of gastrointestinal resection of vagotomy. 4:Patients with a history of irritable bowel syndrome. 5:Patients whose participation in this study would be contraindicated due to complications such as serious hepatic, renal or heart disease. 6:Pregnant patients, possibly pregnant or lactating women. 7:Patients judged as inadequate in participation of this study by their attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GOS Questionnaire after 84-week treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1:The Change of individual score and the improvement of symptom (heartburn,regurgitation) evaluated using GOS/FSSG after4,8-week treatment 2:The improvement of symptom (epigastric pain, nausea, vomiting) evaluated using GOS/FSSG after 4,8-week treatment 3:Treatment response evaluated by GOS/FSSG after 4,8-week treatment | — |
Countries
Japan
Contacts
Public ContactMasahiro Hirano
Hirano Gastroenterology Clinic Gastroenterology
Outcome results
None listed